Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Fitch, Tom R. , Kim, George P. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N044J
Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Reid, Joel M. , Morlan, Bruce W. , Farr, Gist H. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N0041
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer Alberts, Steven R. , Sargent, Daniel J. , Nair, Suresh ... - - JAMA - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N0147
Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Leukemia - 2012 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0682
External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. Apolo, Andrea Borghese , Philips, George , Ostrovnaya, Irina ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90102
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993) Atherton, Pamela J. , Burger, Kelli N. , Loprinzi, Charles L. ... - - Support Care Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N0993
Measurement of Affective and Activity Pain Interference Using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903 Atkinson, Thomas M. , Halabi, Susan , Bennett, Antonia V. ... - - Pain Med - 2012 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-70903
A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502
A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101 Baldwin, R. Michael , Owzar, Kouros , Zembutsu, Hitoshi ... - - Clin. Cancer Res. - 2012 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-40101
Phase III evaluation of American ginseng (panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N07C2 Barton, D. L. , Liu, H. , Dakhil, S. R. , Linquist, B. M. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N07C2
Effect of age on the pharmacokinetics of busulfan (Bu): An Alliance study. Beumer, J. H. , Lewis, L. D. , Owzar, K. , Jiang, C. , Holleran, J. L. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - PPP - CALGB-10503 , CALGB-19808 , CALGB-100103
Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52 Bolton, J. S. , O'Connell, M. J. , Mahoney, M. R. , Farr, G. H. Jr ... - - Clin Colorectal Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-924652
The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial Boughey, J. , Suman, V. , Mittendorf, E. , Ahrendt, G. , Wilke, L. ... - - Cancer Res. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
LACE-Bio: validation of prognostic role of tumour lymphocytic infiltration in resectable non small cell lung cancer Brambilla, E. , Domerg, C. , Lantuejoul, S. , Kratzke, R. ... - - J Thorac Oncol - 2012 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633
Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392) Chauhan, C. , Atherton, P. J. , Satele, D. , Dueck, A. C. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Health Outcome - NCCTG-N0392
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia Claus, R. , Lucas, D. M. , Stilgenbauer, S. , Ruppert, A. S. , Yu, L. ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9712
Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803) Cohen, Harvey Jay , Lan, Lan , Archer, Laura ... - - J Geriatr Oncol - 2012 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - C70103 , CALGB-70803
A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy in Node Negative Non-Small Cell Lung Cancer Cuffe, Sinead , Bourredjem, Abderrahmane , Graziano, Stephen ... - - J Thorac Oncol - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Czuczman, M S , Leonard, J P , Jung, S , Johnson, J L , Hsi, E D ... - - Ann. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50402
Optimal Management of Malignant Pleural Effusions (Results of CALGB 30102) Demmy, Todd L. , Gu, Lin , Burkhalter, Jack E. , Toloza, Eric M. ... - - J Natl Compr Canc Netw - 2012 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30102
A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502 Devine, S. M. , Owzar, K. , Blum, W. , Deangelo, D. , Stone, R. M. ... - ASH - ASH Annual Meeting Abstracts - 2012 Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100103
Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production Ding, W. , Shanafelt, T. D. , Lesnick, C. , Sassoon, T. , Secreto, C. ... - ASH - Blood - 2012 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - N1087
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report Dudek, A. Z. , Pang, H. , Kratzke, R. A. , Otterson, G. A. ... - - J Thorac Oncol - 2012 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30601
Validity and reliability of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Dueck, A. C. , Mendoza, T. R. , Mitchell, S. A. , Reeve, B. B. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - Comprehensive
N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2) Dy, G. K. , Molina, J. , Qi, Y. , Ansari, R. H. , Thomas, S. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821
CYFRA 21-1 as a prognostic and predictive marker in advanced non-small cell lung cancer in a prospective trial: CALGB 150304 Edelman, Martin J. , Hodgson, Lydia , Rosenblatt, Paula Y. ... - - J Thorac Oncol - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150304
Heritable polymorphism predisposes to high expression of BAALC in cytogenetically normal acute myeloid leukemia (CN-AML) Eisfeld, Ann-Kathrin , Marcucci, G. , Liyanarachchi, S. , Döhner, K. ... - AACR - AACR Annual Meeting - 2012 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665
Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia Eisfeld, Ann-Kathrin , Marcucci, Guido , Liyanarachchi, Sandya ... - - Proc. Natl. Acad. Sci. U.S.A - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-9665
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia Eisfeld, Ann-Kathrin , Marcucci, Guido , Maharry, Kati ... - - Blood - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-9665
Whole-genome analysis informs breast cancer response to aromatase inhibition Ellis, M. J. , Ding, L. , Shen, D. , Luo, J. Q. , Suman, V. J. ... - - Nature - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - PPP - ACOSOG-Z1031
Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10% Ellis, M. J. , Suman, V , McCall, L. , Luo, R. , Hoog, J. , Brink, A. ... - AACR - Cancer Res. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657 Esserman, L. J. , Berry, D. A. , Demichele, A. , Carey, L. ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007 , CALGB-150012 , ACRIN-6657
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Esserman, Laura J. , Berry, Donald A. , Cheang, Maggie C. U. ... - - Breast Cancer Res. Treat - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: A randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non–small cell lung cancer Fernando, Hiran C. ... - - J. Thorac. Cardiovasc. Surg. - 2012 Manuscript - No-Endpoint Endpoint - Trial-Description-Only Analysis - Respiratory - ACOSOG-Z4099
Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set Fibla, Juan J. , Cassivi, Stephen D. , Brunelli, Alessandro ... - - Lung Cancer - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 Franko, Jan , Shi, Qian , Goldman, Charles D. , Pockaj, Barbara A. ... - - J Clin Oncol - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9841 , N9741
Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907 Freedman, R. , Pitcher, B. , Keating, N. , Barry, W. , Ballman, K. ... - - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-49907
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study Friday, Bret B. , Anderson, S. Keith , Buckner, Jan , Yu, Chunrong ... - - Neuro Oncol - 2012 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0779
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) Gajewski, T. F. , Salama, A. K. , Niedzwiecki, D. , Johnson, J. ... - - J Transl Med - 2012 Manuscript - Primary Endpoint - Primary Analysis - Experimental - CALGB-500104
Treatment-influenced associations of PML-RARalpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia Gallagher, R. E. , Moser, B. K. , Racevskis, J. , Poire, X. ... - - Blood - 2012 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C9710
A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial Garcia-Aguilar, Julio , Shi, Qian , Thomas, Charles R. , Chan, Emily ... - - Ann. Surg. Oncol. - 2012 Manuscript - Primary Endpoint - Preliminary Analysis - GI - ACOSOG-Z6041
Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial Grogan, E. , Deppen, S. , Ballman, K. , Andrade, G. , Verdail, F. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4031
LACE-Bio Pooled Analysis of the Prognostic and Predictive Value of TP53 mutations in Completely Resected Non Small Cell Lung Cancer (NSCLC) Hainaut, P. , Ma, X. , Lacas, B. , Tsao, M. , Douillard, J.-Y. ... - ESMO - - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633
Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Halabi, S. , Kelly, W. K. , Kaplan, E. B. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401
Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy Harzstark, A. L. , Halabi, S. , Kelly, W. K. , Morris, M. J. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401
A comparison of two methodologies to quantify Thymidylate synthase for predicting survival in patients with colorectal cancer treated on CALGB 89803 Hasson, R. M. , Niedzwiecki, D. ... - AACR - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC) Heist, R. C. Suk , Wang, X. , Hodgson, L. D. , Otterson, G. A. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30704
Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial Holtan, Shernan G. , Steen, Preston D. , Foster, Nathan R. ... - - PLoS ONE - 2012 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N004E
Benefits and Adverse Events in Younger Versus Older Patients Receiving Adjuvant Chemotherapy for Colon Cancer: Findings From the Adjuvant Colon Cancer Endpoints Data Set Hubbard, Joleen , Thomas, David M. , Yothers, Greg , Green, Erin ... - - J. Clin. Oncol - 2012 Manuscript - Secondary Endpoint - Comprehensive Analysis - GI - ACCENT , CALGB-89803
Factors Associated with Local-Regional Recurrence Following a Negative Sentinel Node Dissection: Results of the ACOSOG Z0010 Trial Hunt, Kelly K. , Ballman, Karla V. , McCall, Linda M. ... - - Ann. Surg. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL Hylton, Nola M. , Blume, Jeffrey D. , Bernreuter, Wanda K. ... - - Radiology - 2012 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-150007
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303 Innocenti, Federico , Owzar, Kouros , Cox, Nancy L. , Evans, Patrick ... - - Clin. Cancer Res. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-80303 , C151006
Phase I Trial of Rituximab, Cladribine and Temsirolimus (RCT) for Initial Therapy of Mantle Cell Lymphoma Inwards, D. J. , Fishkin, P. , Laplant, B. R. , Drake, M. T. ... - ASH - ASH Annual Meeting Abstracts - 2012 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - N078D
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Jahan, Thierry , Gu, Lin , Kratzke, Robert , Dudek, Arkadiusz ... - - Lung Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30107
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial Janne, P. A. , Wang, X. F. , Socinski, M. A. , Crawford, J. ... - - J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30406
Prognostic and Predictive Values of KRAS in EGFR-based Subgroups and Combined with P53 in Completely Resected Non-Small Cell Lung Cancer (NSCLC): a LACE-Bio Study Janne, P. , Shepherd, F. , Domerg, C. , Le Teuff, G. , Kratzke, R. ... - - Ann. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633
A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites (N04C2) Jatoi, Aminah , Nieva, Jorge J. , Qin, Rui , Loprinzi, Charles L. ... - - Oncology - 2012 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N04C2
Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) Kelly, W. K. , Halabi, S. , Carducci, M. A. , George, D. J. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401 Kelly, William Kevin , Halabi, Susan , Carducci, Michael ... - - J. Clin. Oncol - 2012 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-90401
North Central Cancer Treatment Group phase II study of panitumumab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer Kim, G. P. , Foster, N. R. , Haddock, M. G. , Dakhil, S. R. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - GI - N064A
Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer (BC) Klepin, H. D. , Pitcher, B. , Ballman, K. V. , Kimmick, G. G. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-70103 , CALGB-49907
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Kostakoglu, Lale , Schöder, Heiko , Johnson, Jeffrey L ... - - Leuk. Lymphoma - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50203
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group Kutny, M. A. , Moser, B. K. , Laumann, K. , Feusner, J. H. , Gamis, A. ... - - Pediatr Blood Cancer - 2012 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C9710
Phase I randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study Laack, N. N. , Galanis, E. , Leinweber, C. , Buckner, J. C. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0877
Utility of circulating biomarkers as outcome predictors in metastatic colorectal cancer and recurrent glioblastoma multiforme patients treated with bevacizumab/sorafenib Lafky, J. M. , Anderson, S. K. , Morlan, B. W. , Nelson, G. D. ... - AACR - Cancer Res. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N054C
Multicenter I-SPY 1 TRIAL (CALGB 150007/150012): Breast cancer stem cells are associated with intrinsic chemoresistance and worse survival Landis, M. , Yau, C. , Neumeister, V. , Rimm, D. , Esserman, L. ... - - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007 , CALGB-150012
Role of axillary ultrasound after neoadjuvant chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis (ACOSOG Z1071) Le-Petross, H. T. , Mccall, L. , Hunt, K. , Mittendorf, E. A. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. Leonard, J. , Jung, S.-H. , Johnson, J. L. , Bartlett, N. L. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50401
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML Li, Z. , Huang, H. , Li, Y. , Jiang, X. , Chen, P. , Arnovitz, S. ... - - Blood - 2012 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C9665
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840 Lichtman, S. M. , Hurria, A. , Cirrincione, C. T. , Seidman, A. D. ... - - Ann. Oncol - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - CALGB-9342 , CALGB-9840
Impact of a Telephone-Based Physical Activity Intervention upon Exercise Behaviors and Fitness in Cancer Survivors Enrolled in a Cooperative Group Setting Ligibel, Jennifer A. , Meyerhardt, Jeffrey , Pierce, John P. ... - - Breast Cancer Res. Treat. - 2012 Manuscript - Primary Endpoint - Primary Analysis - Prevention - NCT00548236
A Phase II Study Of Induction Chemotherapy Followed By Thoracic Radiotherapy (TRT) And Erlotinib In Poor-risk Stage III Non-small Cell Lung Cancer (NSCLC): Initial Results Of CALGB 30605 And RTOG 0972 Lilenbaum, R. , Samuels, M. , Kong, F. , Wang, X. , Janne, P. ... - - J Thorac Oncol - 2012 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30605
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial) Lin, Cheryl , Buxton, Meredith Becker , Moore, Dan , Krontiras, Helen ... - - Breast Cancer Res. Treat. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007 , CALGB-150012
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer Lips, Esther H. , Mukhtar, Rita A. , Yau, Christina ... - - Breast Cancer Res. Treat. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 Liu, Hongtao , Johnson, Jeffrey L. , Koval, Greg , Malnassy, Greg ... - - Haematologica - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-59909
PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy Liu, M. , Pitcher, B. , Mardis, E. , Davies, S. , Snider, J. ... - AACR - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-9741
The genetic landscape of mutations in Burkitt lymphoma Love, Cassandra , Sun, Zhen , Jima, Dereje , Li, Guojie , Zhang, Jenny ... - - Nat. Genet. - 2012 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10002
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study Lozanski, Gerard , Ruppert, Amy S. , Heerema, Nyla A. ... - - Leuk. Lymphoma - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-9712 , CALGB-9665
NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial. Ma, D. , Galanis, E. , Schiff, D. , Wu, W. , Peller, P. J. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - N057K
Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901 Mandelblatt, J. S. , Faul, L. A. , Luta, G. , Makgoeng, S. B. ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Older Adult - CALGB-369901
Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer Mandrekar, Sumithra J. , Foster, Nathan R. , Qi, Yingwei ... - ASCO - J. Clin. Oncol. - 2012 Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Respiratory - N0424
Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia Marcucci, Guido , Metzeler, Klaus H. , Schwind, Sebastian ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-9621 , CALGB-19808
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma McCarthy, Philip L. , Owzar, Kouros , Hofmeister, Craig C. ... - - N. Engl. J. Med. - 2012 Manuscript - Primary Endpoint - Primary Analysis - Myeloma - CALGB-100104
Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence Mccarter, M. D. , Antonescu, C. R. , Ballman, K. V. , Maki, R. G. ... - - J. Am. Coll. Surg. - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - ACOSOG-Z9000 , ACOSOG-Z9001
Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial Mcwilliams, R. R. , Mahoney, M. R. , Marchello, B. T. , Jatoi, A. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - GI - N0543
A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147. Mcwilliams, R. R. , Mahoney, M. R. , Sargent, D. J. , Nelson, G. D. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0147
RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures Mendler, Jason H. , Maharry, Kati , Radmacher, Michael D. ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , CALGB-8461 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9665 , CALGB-9720 , CALGB-10201 , CALGB-19808 , CALGB-20202
Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803 Meyerhardt, J. A. , Sato, K. , Niedzwiecki, D. , Ye, C. , Saltz, L. B. ... - - J Natl Cancer Inst - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Prevention - CALGB-89803 , CALGB-159806
Evaluation of the stage IB designation of the 7th edition of the AJCC staging system: Biologic factors are more important Mittendorf, E. , Ballman, K. , Mccall, L. , Hansen, N. , Lucci, A. ... - ASCO - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782 Monk, J.P. , Halabi, S. , Picus, J. , Hussain, A. , Philips, G. ... - - Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-9782
N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC) Moreno-Aspitia, A. , Rowland, K. M. Jr , Allred, J. B. , Liu, H. ... - AACR - Cancer Res. - 2012 Abstract - Primary Endpoint - Preliminary Analysis - Breast - N0937
Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501) Morrison, V. A. , Jung, S.-H. , Johnson, J. , Lacasce, A. ... - ASH - ASH Annual Meeting Abstracts - 2012 Abstract - Primary Endpoint - Preliminary Analysis - Lymphoma - CALGB-50501
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia Mrózek, Krzysztof , Marcucci, Guido , Nicolet, Deedra ... - - J. Clin. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-19808 , CALGB-8461 , CALGB-8525 , CALGB-8923 , CALGB-9420 , CALGB-9621 , CALGB-9720
Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL) Muffly, L. S. , Stock, W. , Breitenbach, K. , Mulkey, F. , Luger, S. ... - ASH - Blood - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Disparities - CALGB-10403 , C10403
Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803 Ogino, Shuji , Shima, Kaori , Meyerhardt, Jeffrey A. ... - - Clin Cancer Res - 2012 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803 , C150705
Randomized Clinical Trial of Imiquimod: An Adjunct to Treating Cervical Dysplasia Pachman, Deirdre R. , Barton, Debra L. , Clayton, Amy H. ... - - Am J Obstet Gynecol - 2012 Manuscript - Primary Endpoint - Primary Analysis - Prevention - NCCTG-989251
Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study Perez, E. , Eckel-Passow, J. , Ballman, K. , Anderson, S. ... - AACR - Cancer Res. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831
Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria Perez, Edith A. , Dueck, Amylou C. , McCullough, Ann E. ... - - J Natl Cancer Inst - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Smoking status and prognosis in patients with stage III colon cancer: A correlative analysis of NCCTG phase III trial N0147 Phipps, A. I. , Shi, Q. , Limburg, P. L. J. , Nelson, G. D. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - GI - N0147
A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes1:NCCTG N08C7 Pruthi, Sandhya , Qin, Rui , Terstreip, Shelby A. , Liu, Heshan ... - - Menopause - 2012 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N08C7
Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer Qi, Y. , Ziegler, K. L. Allen , Hillman, S. L. , Redman, M. W. ... - - Cancer - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - N0022 , N0026 , N0222 , N0323 , N0326 , N0426 , N0528 , N0626 , N0821 , N9921
A phase II study of neoadjuvant therapy with cisplatin, docetaxel, panitumumab plus radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051) Reed, C. , Decker, P. , Schefter, T. , Meyers, B. , Ferguson, M. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Preliminary Analysis - GI - ACOSOG-Z4051
Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Reeves, Brandi N , Dakhil, Shaker R , Sloan, Jeff A , Wolf, Sherry L ... - - Cancer - 2012 Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Symptom Inter - N08C1
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials Reiman, T. , Lai, R. , Veillard, A. S. , Paris, E. , Soria, J. C. ... - - Ann. Oncol. - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. Reungwetwattana, Thanyanan , Molina, Julian R ... - - J Thorac Oncol - 2012 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0323
EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial. Rimm, D. L. , Ballman, K. , Cheng, H. , Vassilakopoulou, M. , Chen, B. ... - - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - N9831
Identification of Potential Prognostic Biomarkers in Patients with Untreated, Advanced Pancreatic Cancer from a Phase III Trial (CALGB 80303) Roberts, Andrew S. , Campa, Michael J. , Gottlin, Elizabeth B. ... - - Cancer - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-80303
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). Romanus, Dorothy , Kindler, Hedy L , Archer, Laura , Basch, Ethan ... - - J Pain Symptom Manage - 2012 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - CALGB-80303
Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831 Romond, E. H. , Suman, V. J. , Jeong, J.-H. , Sledge, G. ... - - Cancer Res. - 2012 Abstract - Primary Endpoint - Comprehensive Analysis - Breast - N9831
BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance) Rubenstein, J. L. , Hsi, E. D. , Johnson, J. L. , Jung, S.-H. ... - ASH - ASH Annual Meeting Abstracts - 2012 Abstract - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50202
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907) Ruddy, K. J. , Pitcher, B. N. , Archer, L. E. , Cohen, H. J. ... - - Ann. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Experimental - CALGB-49907 , CALGB-60104
CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC) Rugo, H. S. , Barry, W. T. , Moreno-Aspitia, A. , Lyss, A. P. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40502 , NCCTG-N063H
An Interim Analysis Of CALGB 150607: Expression And Mutational Status Of c-MET, HGF, EGFR, KRAS, p53, c-CBL, And E-cadherin In Resected Lung Adenocarcinoma Specimens Salgia, R. , Nallasura, V. , Pang, H. , Rolle, C. , Richards, W. ... - Chicago MSTO - Clin. Cancer Res. - 2012 Abstract - Secondary Endpoint - Preliminary Analysis - Correl Sci NOS - CALGB-150607
Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis Schild, S. E. , Foster, N. R. , Meyers, J. P. , Ross, H. J. ... - - Ann. Oncol. - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - NCCTG-86-20-51 , NCCTG-89-20-51 , NCCTG-89-20-52 , NCCTG-95-20-53
N0321: A phase II study of bortezomib, paclitaxel, carboplatin, and radiotherapy for locally advanced non-small cell lung cancer Schild, S. E. , Molina, J. R. , Dy, G. K. , Rowland, K. M., Jr ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0321
Long-term Survival of Patients (pts) Treated with High-dose Radiotherapy(rt) and Concurrent Chemotherapy for Unresectable Non-small Cell Lung Cancer (nsclc) Schild, S. , Hillman, S. , Graham, D. , Vora, S. , Garces, Y. ... - MSTO - J Thorac Oncol - 2012 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Respiratory - NCCTG-N0028
Association study of the let-7 microrna-binding site polymorphism in 3-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147 Sha, D. , Lee, A. , Shi, Q. , Steven, A. R. , Sargent, D. J. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0147
Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study. Shepherd, F. A. , Bourredjem, A. , Brambilla, E. , Domerg, C. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633
Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101 Shulman, L. N. , Cirrincione, C. T. , Berry, D. A. , Becker, H. P. ... - - J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40101
Randomized phase II study of two doses of pixantrone in patients with metastatic breast cancer, N1031 Alliance. Sideras, K. , Moreno-Aspitia, A. , Tenglin, R. C. , Liu, H. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N1031
North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane Sideras, Kostandinos , Dueck, Amylou C. , Hobday, Timothy J. ... - - Clin. Breast Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0537
Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX +/- cetusimab: NCCTG N0147. Sinicrope, F. A. , Mahoney, M. R. , Smyrk, T. C. , Thibodeau, S. N. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0147
Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials Sinicrope, Frank A. , Foster, Nathan R. , Yoon, Harry H. ... - - J Clin Oncol - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N994C
Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147). Sloan, J. A. , Shi, Q. , Lee, A. , Diasio, R. B. , Pavey, E. S. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - NCCTG-N0147
The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401). Small, E. J. , Halabi, S. , Carducci, M. A. , Ryan, C. J. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401
CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN) Smith, Ellen M. Lavoie , Pang, Herbert , Cirrincione, Constance ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Onc Nursing - CALGB-170601
Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population Soulos, Pamela R. , Yu, James B. , Roberts, Kenneth B. ... - - J. Clin. Oncol - 2012 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Older Adult - CALGB-9343
Phase I study of panobinostat (LBH589) and letrozole in post-menopausal women with metastatic breast cancer. Tan, W. , Allred, J. , Moreno-Aspitia, A. , Northfeld, D. , Ingle, J. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N093B
Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial Tan, Winston W. , Allred, Jacob B. , Salim, Muhammad , Flynn, Patrick ... - - Clin. Breast Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0337
A novel interaction of genotype, gender and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803 Warren, R. S. , Atreya, C. E. , Niedzwiecki, D. , Mayer, R. J. ... - - J. Clin. Oncol. - 2012 Abstract - Secondary Endpoint - Primary Analysis - GI - C89803
Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance) Wetzler, M. , Watson, D. , Stock, W. , Owzar, K. , Koval, G. , Hoke, E. ... - - Blood - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10001
Adverse Prognostic Impact of GAS6 Expression in De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance) Whitman, S. , Kohlschmidt, J. , Maharry, K. , Nicolet, D. ... - - Blood - 2012 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9665 , CALGB-20202
The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia Whitman, SP , Caligiuri, MA , Maharry, K , Radmacher, MD ... - - Leukemia - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-10201 , CALGB-8525 , CALGB-8923 , CALGB-9420 , CALGB-9720
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype Wilson, W. H. , Jung, S. H. , Porcu, P. , Hurd, D. , Johnson, J. ... - - Haematologica - 2012 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50103
Gene expression changes associated with response to neoadjuvant chemotherapy are observed early in treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Wolf, D. , Yau, C. , Magbanua, M. , Boudreau, A. , Davis, S. , Haqq, C. ... - - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007 , CALGB-150012
The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA Wolf, S. L. , Barton, D. L. , Qin, R. , Wos, E. J. , Sloan, J. A. ... - - Support Care Cancer - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Health Outcome - N06CA
Relationship between overall survival and progression-free survival for recent NCCTG glioblastoma multiforme trials Wu, W. , Galanis, E. , Buckner, J. C. , Jaeckle, K. A. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Neuro-Onc - Comprehensive
Protein pathway activation mapping of I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with HR+/HER2– tumors Wulfkuhle, J. , Yau, C. , Gallagher, R. , Wolf, D. , Calvert, V. ... - SABCS - Cancer Res. - 2012 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007 , CALGB-150012
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping Wulfkuhle, Julia D. , Berg, Daniela , Wolff, Claudia , Langer, Rupert ... - - Clin. Cancer Res. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-150007
